Talk:IDH1

Glioblastoma and IDH1mt
The article talks in several places about Glioblastoma Multiform (GBM) with the IDH1 mutation. In fact, the 2021 WHO guidelines for glioma redefined the various subtypes of glioma according to their mutations. A glioma with mutated IDH1 is now an astrocytoma or an oligodendroglioma by definition. Similarly, a GBM must be IDH1 wildtype. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896839/

I'm a newbie here and don't know how to fix this. — Preceding unsigned comment added by Kevlaw (talk • contribs) 16:12, 5 July 2024 (UTC)

Untitled
Hi, I was thinking of doing a small edit to this page to add information regarding the IDH1 mutation in cancer and it’s implications. This is my first edit to a wikipedia page so if there is anything I should change please let me know.

IDH1 mutations are heterozygous, typically involving a single amino acid substitution in the active site of the enzyme in codon 132. The mutation results in a loss of normal enzymatic function and the abnormal production of 2-hydroxyglutarate (2-HG). 2-HG has been found to inhibit enzymatic function of many alpha-ketoglutarate dependent dioxygenases, including histone demethylases, causing widespread changes in histone methylation.

Thanks,

Mbanting (talk) 15:38, 20 September 2015 (UTC)

Hi, I will be editing this page for AdGen 3595 at the University of Western Ontario and I will be adding information about mutations in "IDH1", the implications and the clinical relevance of these mutations, as well as some accepted research findings based on review articles.

Review papers I will use:
 * Liu X & Ling ZQ (2015). Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors. Histology Histopathology 30, 1155-1160.


 * Dimitrov L, Hong C, Yang C, Zhuang Z & Heiss J (2015). New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. International Journal of Medical Sciences 12, 201-213.


 * Horbinski C (2013). What do we know about IDH1/2 mutations so far, and how do we use it?. Acta Neuropathologica 125, 621-636.


 * Huse J & Aldape K (2014). The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. Clinical Cancer Research 20, 5601-5611.


 * Turkalp Z, Karamchandani J & Das S (2014). IDH Mutation in Glioma. JAMA Neurology 71, 1319.


 * Waitkus M, Diplas B & Yan H (2015). Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology 0, 1-11.

If anyone has any suggestions as to how to conduct this edit or what to add please let me know! Mbanting (talk) 21:59, 10 October 2015 (UTC)

I added a great deal to there article, but am unsure about whether I should move it to mainspace. Here is a link to my sandbox should anyone want to further improve the article : https://en.wikipedia.org/wiki/User:Mbanting/sandbox

Mbanting (talk) 17:06, 10 January 2016 (UTC)

Wiki Education Foundation-supported course assignment
This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Mbanting.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 12:16, 18 January 2022 (UTC)